Mostrar el registro sencillo del ítem

Failure of tibolone to potentiate the pharmacological effect of fluoxetine in postmenopausal major depression

dc.creatorBerlanga, Carlos
dc.creatorMendieta, Danelia
dc.creatorAlva, Guadalupe
dc.creatorLara, María del Carmen
dc.date.accessioned2017-06-29T04:30:23Z
dc.date.available2017-06-29T04:30:23Z
dc.date.issued2003es_ES
dc.identifier396es_ES
dc.identifier.issn1540-9996es_ES
dc.identifier.urihttp://repositorio.inprf.gob.mx/handle/123456789/5087
dc.identifier.urihttps://doi.org/10.1089/154099903321154121es_ES
dc.language.isoenges_ES
dc.relation21 (1) 33-39 p.es_ES
dc.relationversión del editores_ES
dc.rightsacceso cerradoes_ES
dc.titleFailure of tibolone to potentiate the pharmacological effect of fluoxetine in postmenopausal major depressiones_ES
dc.typearticlees_ES
dc.contributor.affiliationNational Institute of Psychiatry, Ramón de la Fuente Clinical Research Divisiones_ES
dc.contributor.emailcisnerb@imp.edu.mxes_ES
dc.relation.jnabreviadoJ WOMENS HEALTHes_ES
dc.relation.journalJournal of women's healthes_ES
dc.identifier.placeEstados Unidoses_ES
dc.date.published2003es_ES
dc.identifier.organizacionInstituto Nacional de Psiquiatría Ramón de la Fuente Muñizes_ES
dc.description.monthEne-Febes_ES
dc.description.abstractotrodiomaBACKGROUND: Perimenopausal depression has been attributed to physiological progressive estrogen decline. Estrogen and derivatives have some mood-enhancing effects, although studies of using estrogen as an antidepressant have had mixed results. The gonadomimetic drug tibolone stimulates estrogen receptors in a tissue-selective fashion, increasing the gonadal activity without causing some of the usual side effects of other estrogen preparations. METHODS: A total of 31 postmenopausal outpatients with a major depressive disorder (MDD) participated in the study. Sixteen received the antidepressant fluoxetine (20 mg/day) plus tibolone (2.5 mg/day), and 15 received the same dose of fluoxetine plus placebo, assigned in a randomized fashion. RESULTS: After 8 weeks of treatment, the two groups had a similar level of improvement in their depressive symptoms. Both treatments were well tolerated, without significant side effects. Pretreatment and posttreatment serum hormonal levels did not predict the final response. CONCLUSIONS: Combining tibolone and fluoxetine did not represent a more robust antidepressant response than fluoxetine alone in postmenopausal women with MDD.es_ES
dc.subject.meshmAgedes_ES
dc.subject.meshmDepressive Disorderes_ES
dc.subject.meshmbloodes_ES
dc.subject.meshmdrug therapyes_ES
dc.subject.meshmDouble-Blind Methodes_ES
dc.subject.meshmEstrogen Receptor Modulatorses_ES
dc.subject.meshmtherapeutic usees_ES
dc.subject.meshmEstrogenses_ES
dc.subject.meshmFemalees_ES
dc.subject.meshmFluoxetinees_ES
dc.subject.meshmtherapeutic usees_ES
dc.subject.meshmHumanses_ES
dc.subject.meshmMexicoes_ES
dc.subject.meshmMiddle Agedes_ES
dc.subject.meshmNorpregneneses_ES
dc.subject.meshmPostmenopausees_ES
dc.subject.meshmSerotonin Uptake Inhibitorses_ES


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem